Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + Sintilimab + Nab-paclitaxel in First-line TNBC
NCT06140576Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in triple-negative breast cancer (TNBC), sponsored by Zhejiang Cancer Hospital. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
lenvatinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06140576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06140576.